How effective is rituximab for ITP?

The use of rituximab for idiopathic thrombocytopenic purple (ITP) is relatively effective, but it is not the first line treatment. Most patients with ITP respond positively to splenectomy and require no further treatment after surgery. Rituximab for ITP is considered only after splenectomy does not cause a positive effect. Research shows that approximately 30 to 40 percent of patients treated with drug require no further treatment. The drug is quite safe and only about 27.5 percent of patients who experience side effects on treatment. Studies

The effects of rituximab for ITP show that 30 to 40 percent of patients do not require any additional treatment for the condition. Approximately 60 percent of patients have an initial positive response, but some conditions require additional attention. These results mean that rituximab for ITP is possible for ITP, but by no means this is not the best treatment. Doctors may decide to use a medicine, but only after the spacians did not respond to other methods of treatment.

Research on the effects of rituximab for ITP has revealed that the drug is more effective in younger patients and those who have been undergoing less previous treatment. To znamená, že lék může být účinnější, pokud se používá jako léčba první linie. Studies conducted in its effects have not shown the same degree of positive answers as splenectomy, so it is unlikely to be used as a first -line treatment. Lékaři se však mohou častěji rozhodnout používat lék při léčbě mladších pacientů.

Bezpečnost používání rituximabu pro ITP byla zkoumána v klinických studiích. Studie ukázaly, že přibližně 21 procent pacientů, kterým je podáván lék, bude mít drobné nežádoucí účinky. Většina těchto reakcí nastane, když je lék poprvé infundován. Méně než 4 procenta pacientů zažívá závažné reakce, když tAking rituximab. Podle výzkumu dochází u smrt u 2,5 procenta pacientů užívajících lék.

splenektomie je mnohem účinnější léčba než rituximab pro ITP. The procedure has shown consistent efficiency in approximately two -thirds of patients. Most doctors use splenectomy as a first -line treatment for ITP because most patients require no additional treatment after the procedure. It is also used much longer than rituximab, so evidence of its efficiency is more reliable. Splenectomy is complete or partial removal of the spleen.